Clinical Trial: Contrast-Enhanced Ultrasound for Early Assessment of Microwave Ablation in HCC

U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07598331) titled 'Contrast-Enhanced Ultrasound for Early Assessment of Microwave Ablation in HCC' on May 13.

Brief Summary: Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the fourth leading cause of cancer-related deaths worldwide [1]. Although surgical resection remains the reference curative therapy, ultrasound-guided microwave ablation (MWA) yields comparable oncologic outcomes [2,3] and is endorsed as a first-line option in several national and international guidelines. A sufficient ablative ablation margins (AM) is pivotal for preventing local tumour progression (LTP) [4,5].

According to current consensus, technical succe...